By Jeff Stevens, CEO and co-founder of Psyched Wellness
Psychedelics have made their comeback. More than 40 years after the war on drugs shut down all mainstream applications of psilocybin and others, the space is blooming with hope and promise again. We see states in the U.S. adopting and designing laws and regulations that will facilitate the spread of psychedelic therapies.
There is also a worldwide shift that is hard to ignore: earlier this year, Australia became the first country to recognize several psychedelic compounds as legal for therapy-resistant depression and PTSD. Other nations, Brazil, for instance, have long been pioneers in embracing practices and substances, including psilocybin, most commonly found in “magic mushrooms” or even DMT, the compound found in ayahuasca brews.
Research communities are now expanding the scope of their studies around psychedelics, exploring areas outside psychiatry. Arizona is about to become the first state to sponsor controlled clinical trials of whole psilocybin mushrooms as a recently introduced bill aims to expand research into areas like the treatment of long COVID, among others. These are strong indicators we still don’t know the full potential of these drugs.
And there are other product segments worth paying …